COMUNICADO: Roche crea una terapia hormonal más herceptina para el cáncer de mama positivo avanzado HER2 (y 2)

-- Acerca de Genentech: www.gene.com

-- Roche en oncología: http://www.roche.com/mboncology-e.pdf

-- Roche Health Kiosk sobre el cáncer: www.health-kiosk.ch/start_krebs

Para acceder a los vídeoclips, en emisiones estándar, libres de gastos, visite: www.thenewsmarket.com.

Referencias

[1] Kaufman, B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) Congress, Abstract no. LBA2, 2006.

[2] Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002.

[3] Marty M, Cognetti F, Maraninchi D, et al. Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: Results of a Randomised Phase II Trial by the M77001 Study Group. J Clin Oncol. 2005;23:4265-4274.

[4] Organización Mundial de la Salud, 2000.

Roche Group Media Office, teléfono: +41-61688-8888 / e-mail: basel.mediaoffice@roche.com, - Baschi Dürr, - Alexander Klauser, - Daniel Piller (responsable de la Roche Group Media Office), - Katja Prowald (responsable de R&D Communications), - Martina Rupp.